5
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Adrenal steroid responses to naloxone in polycystic ovarian disease

, , , &
Pages 355-361 | Published online: 07 Jul 2009
 

Abstract

In order to investigate the role of the adrenal gland in the pathogenesis of polycystic ovarian disease (PCOD), we evaluated the adrenal steroid response to an opiate receptor blockade.

Six healthy menstruating volunteers and 6 patients with PCOD were given a saline or naloxone (4 tng i.v.) injection in the early follicular phase. Blood samples were taken prior to the injections and every 15–30 minutes in the following 2 hours. Cortisol, androstenedione (A) and dehydroepiandrosterone (DHA) plasma levels were determined by RIA after extraction (cortisol) and celite chromatography (A and DHA).

While in controls naloxone increased only cortisol concentrations, in PCOD patients DHA plasma levels also were stimulated by the opiate receptor antagonist. In PCOD patients the increase of cortisol (p < 0.05) and of DHA (p < 0.001) levels resulted significantly higher than in controls. In both groups A plasma levels remained unchanged after naloxone administration.

These data confirm that endogenous opioids exert an inhibitory control on the pituitary-adrenal axis. In PCOD patients the response to naloxone led to a hypersecretion of adrenal δ5-androgens, which could account for the development of the syndrome.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.